Clene to Present at the Emerging Growth Conference
Clene (Nasdaq: CLNN), a clinical-stage biopharmaceutical company specializing in mitochondrial health and neuronal protection for neurodegenerative diseases, announced its participation in the Emerging Growth Conference.
The virtual presentation will take place on June 12, 2024, at 2:20 p.m. EDT and includes a corporate presentation with a Q&A session. The webcast will be accessible on Clene's website and a replay will be available on the Emerging Growth YouTube Channel.
The Emerging Growth Conference offers public companies a platform to present their innovations to a broad investor audience, including individual and institutional investors, as well as investment advisors and analysts.
- Clene is presenting at the Emerging Growth Conference, potentially increasing investor visibility.
- The conference presentation includes a Q&A, offering direct engagement with potential investors.
- Replay availability on both Clene's website and the Emerging Growth YouTube Channel extends the reach of the presentation.
- No new clinical data or significant business developments were announced in the PR.
- The PR did not mention any immediate financial impacts or partnerships resulting from the presentation.
- Potential investor interest might be if the presentation content lacks substantial updates or breakthroughs.
SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Virtual Presentation Details
Date: June 12, 2024
Time of Presentation: 2:20 p.m. EDT
Format: Corporate presentation with Q&A
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast, along with accompanying slides, here: https://goto.webcasts.com/starthere.jsp?ei=1658205&tp_key=76d4029138&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.
About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact | Investor Contact |
| Ignacio Guerrero-Ros, Ph.D., or David Schull | Kevin Gardner |
| Russo Partners, LLC | LifeSci Advisors |
| Ignacio.guerrero-ros@russopartnersllc.com | kgardner@lifesciadvisors.com |
| David.schull@russopartnersllc.com | 617-283-2856 |
| (858) 717-2310 |
FAQ
When is Clene presenting at the Emerging Growth Conference?
Where can I view Clene's presentation at the Emerging Growth Conference?
What type of presentation will Clene give at the Emerging Growth Conference?
What is the focus of Clene's business?
What is Clene's stock symbol?
